Psych HealthPGx Panel

DNA strand for Precision Medicine

Psych HealthPGx Panel

Pharmacogenomics testing for mental health

RPRD’s Psych HealthPGx Panel provides broad and actionable insights to help the clinicians make informed treatment decisions. The results of the test may help in choosing the right medications and the appropriate dose for patients undergoing treatments for certain psychiatric conditions, such as depression, anxiety, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). The clinical report that contains the test results also includes additional treatment information for therapeutic areas such as pain management, cancer, and cardiovascular care, strictly based on the guidelines published by Clinical Pharmacogenomics Implementation Consortium (CPIC). Our strictly evidence-based interpretations mean full transparency in how we translate the pharmacogenetic test results into clinically useful interpretations.

Evidence-based

The gene coverage of the panel has been selected and curated by RPRD’s clinicians and scientists following strong peer-reviewed scientific evidence and industry’s highest standards of actionability. The Psych HealthPGx Panel clinical report fully adheres to the recommendations by the CPIC clinical guidelines and the FDA drug labeling, with clear annotations and references.

Created for all ethnicities

The panel covers a broad array of genetic alleles/variants of the key PGx genes, including not only common, but also rare and ethnicity-specific alleles. This broad coverage is particularly important when analyzing diverse populations because overlooking these rare or ethnicity-specific alleles could miss clinically important genetic information for these patients. RPRD’s PGx testing transcends ethnic diversity and generates highly accurate testing results for every patient.

Go beyond mental illness, to care for comorbidities

The panel provides extensive insights beyond treatment regimens with psychotropic medications. It helps clinicians make comprehensive therapeutic decisions when treating patients with various comorbidities.

Gene-drug pairs
Psychiatry DrugsBrand namesAssociated genes
AmitriptylineElavil
CYP2C19, CYP2D6
Atomoxetine
Strattera
CYP2D6
Citalopram
Celexa
COMT, CYP2C19, FKBP5, GRIK4, HTR2A, HTR2C, SLC6A4, TXNRD2
Clomipramine
Anafranil
CYP2C19, CYP2D6
Clozapine
Clozaril
ANKK1, DRD2, MC4R
Desipramine
Norpramin
CYP2D6
Doxepin
Silenor, Zonalon, Prudoxin
CYP2C19, CYP2D6
Escitalopram
Lexapro
COMT, CYP2C19, SLC6A4, TXNRD2
Fluoxetine
Prozac, Sarafem
COMT, FKBP5, TXNRD2
Fluvoxamine
Luvox
COMT, CYP2D6, TXNRD2
Imipramine
Tofranil
CYP2C19, CYP2D6
Mirtazapine
Remeron
FKBP5
Nortriptyline
Pamelor
CYP2D6
Olanzapine
ZyprexaANKK1, DRD2, HTR2C, MC4R, CYP2D6
Paroxetine
Paxil
COMT, CYP2D6, FKBP5, HTR1A, TXNRD2
Risperidone
Risperdal
ANKK1, DRD2, HTR2C, MC4R
Sertraline
Zoloft
COMT, CYP2C19, TXNRD2
Trimipramine
Surmontil
CYP2C19, CYP2D6
Venlafaxine
Effexor
FKBP5
Other DrugsBrand namesAssociated genes
Clopidogrel
Plavix
CYP2C19
Codeine
CYP2D6
DexlansoprazoleDexilant
CYP2C19
Digoxin
Lanoxin, Digox
ABCB1
EsomeprazoleNexium
CYP2C19
FentanylDuragesic, Sublimaze
ABCB1
HydrocodoneZohydro ER
CYP2D6
LansoprazolePrevacidCYP2C19
MethadoneDolophine, MethadoseCYP2D6
Methotrexate
RheumatrexABCB1
Omeprazole
PrilosecCYP2C19
OndansetronZofran
ABCB1
OxycodoneOxycontin, Roxicodone
CYP2D6
Pantoprazole
Protonix
CYP2C19
Rabeprazole
AciphexCYP2C19
TropisetronNavoban
CYP2D6
VoriconazoleVfend
CYP2C19
Nevirapine
ViramuneABCB1
Simvastatin
Zocor
ABCB1
TamoxifenSoltamoxCYP2D6
TramadolUltram, ConzipCYP2D6
Alleles tested
GenesAlleles
ABCB1ABCB1_c.1795G>A(A599T) (rs2235036);
ABCB1_c.239C>A(A80E) (rs9282565);
ABCB1_c.2677G>T/A(A893S/T) (rs2032582);
ABCB1_c.2995G>A(A999T) (rs72552784);
ABCB1_c.1696G>A(E566K) (rs28381902);
ABCB1_c.49T>C(F17L) (rs28381804);
ABCB1_c.3188G>C(G1063A) (rs2707944);
ABCB1_c.554G>T(G185V) (rs1128501);
ABCB1_c.2485A>G(I829V) (rs2032581);
ABCB1_c.2506A>G(I836V) (rs28381967);
ABCB1_c.61A>G(N21D) (rs9282564);
ABCB1_c.131A>G(N44S) (rs1202183);
ABCB1_c.3151C>G(P1051A) (rs28401798);
ABCB1_c.3320A>C(Q1107P) (rs55852620);
ABCB1_c.1777C>T(R593C) (rs28381914);
ABCB1_c.3421T>A(S1141T) (rs2229107);
ABCB1_c.1199G>A(S400N) (rs2229109);
ABCB1_c.3751G>A(V1251I) (rs28364274);
ABCB1_c.2401G>A(V801M) (rs2235039)
ANKK1ANKK1_c.453A>C (rs4938013);
rs7118900; rs1800497
DRD2rs1125394;
rs1124493;
rs6275;
rs1801028;
rs2283265;
rs2440390;
rs4648317;
rs2734841;
rs1076560;
rs1110976;
rs1079598;
rs6277;
rs6279;
rs4436578;
DRD2_c.-32+24002G>A (rs4460839);
rs6279
DRD2_c.285+2169C>T (rs2734833)
FKBP5rs3800373; rs9380524;
rs1360780; rs4713916
GRIK4GRIK4_c.2267-1150G>A (rs12800734);
rs1954787
HTR1Ars10040843; rs6875401; rs6295
rs1364043; rs114058084; rs10042486; chr5:63121377
HTR2Ars9316233; rs7997012; rs6318;
rs6314; rs6313; rs6311; rs518147; rs3813929; rs3813928; rs2497538; rs1414334;
HTR2A_c.614-25509C>T (rs659734);
HTR2A_c.613+8832A>G (rs17288723);
HTR2A_c.516C>T(p.=) (rs6305);
HTR2A_c.-344G>A (rs6312)
HTR2Crs3813929; rs2497538;
HTR2C_c.-238+2217N>T (rs539748);
rs3813928;
rs518147;
rs6318;
rs1414334
MC4Rrs11872992
TXNRD2rs13306278;
rs9606186;
rs2020917
SLC6A4SLC6A4_L/S allele (rs774676466);
rs2531
COMTCOMT_c.1-98A>G(SolublePromoter);
COMT_c.186C>T(H62=);
COMT_c.408C>G(L136=);
COMT_c.472G>A(V158M);
COMT_c.214G>T(A72S);
COMT_c.304G>A(A102T)
CYP2C19*1; *2; *3; *4A; *4B; *5; *6; *7; *8; *9; *10; *12; *13; *14; *15; *16; *17; *18; *19; *22; *23; *24; *25; *26; *28; *34; *35;
CYP2C19_12834G>C(A161P) (rs181297724)
CYP2C19_80248G>A(D360N) (rs144036596)
CYP2C19_19194_19195insG(E241Frameshift) (rs72558185)
CYP2C19_12460G>C(E92D) (rs17878459)
CYP2C19_17814T>C(F168L) (rs28399510)
CYP2C19_90052delG(G439Frameshift)
CYP2C19_12405T>C(M74T) (rs28399505)
CYP2C19_57876C>G(T302R) (rs58259047)
CYP2C19_12690G>A(V113I) (rs145119820)
CYP2C19_80161G>A(V331I) (rs3758581)
CYP2C19_87242G>A(V394M) (rs55948420)
CYP2D6*1; *2; *3A; *3B; *4; *5; *6; *7; *8; *9; *10; *11; *12; *14; *15; *17; *18; *19; *20; *22; *23; *25; *28; *29; *31; *33; *35; *37; *38; *40; *41; *42; *43; *44; *45; *46; *47; *48; *49; *51; *53; *54; *55; *56A; *56B; *59; *62; *70; *71; *72; *73; *75; *81; *82; *84; *85; *86; *88; *89; *95; *100; *101; *102; *103; *107; *109; *114;
CYP2D6_974C>A(L91M) (rs28371703)
CYP2D6_984A>G(H94R) (rs28371704)
CYP2D6_1858C>T(R173C) (rs67780109)
CYP2D6_1976G>A(G212E) (rs5030866)
CYP2D6_2616_2617delA(K281Frameshift) (rs28371720)
CYP2D6_2938C>T(P325L) (rs140513104)
CYP2D6_3265G>A(R365H) (rs1058172)
CYP2D6*52_3877G>A(E418K) (rs28371733)
CYP2D6_3887T>C(L421P) (rs72549345)
CYP2D6_4123C>T(S467L) (rs370012110)
CYP2D6_4131A>G(T470A) (rs1135835)
CYP2D6_4155C>T(H478Y) (rs28371735)
CYP2D6_4180G>C(S486T) (rs1135840)
CYP2D6_4192A>G(Y490C) (rs199722016)

How it works?

We accept whole blood, saliva or buccal swab samples. As a healthcare provider, you can choose to collect the patient’s blood sample or have the patient collect a salvia or buccal swab sample at home with our in-home collection kit. Depending on what option you choose, we offer to send the saliva or buccal swab collection kits either directly to your office or to the patient’s home, free of charge.

Please contact us to set up the process.

Only a fully licensed healthcare provider treating the patient can order the test.

Please download and fill out the Test Requisition Form. Please send the completed TRF together with the patient’s whole blood sample to us or send us the TRF only and we will arrange the sample in-home collection directly with the patient.

RPRD’s pharmacogenomics testing is performed in our fully CLIA-certified clinical grade genetic testing lab.

If it is the first time you send us the patient’s sample, please contact us to establish the process.

Specimen Requirement

RPRD provides a few payment options: billing to the institution or the patient’s insurance provider. Please contact us if you would like to learn more about each of the payment options.

Ready to talk?

If you are ready to get started or still have questions, we are here to help you. Call us at (414)-316-3097 or email info@rprdx.com.

FAQ

All our tests for clinical decision-making should be ordered by a licensed healthcare provider or a genetic counselor. Pharmacists also play a critical role in integrating PGx into patient care. In the United States, in general,  pharmacists need collaborative practice agreements in place to order the test. However, certain states may have specific state laws regulating pharmacists’ ability to order and interpret lab results.

If the specimen meets our quality requirements, typical turnaround time for the test is 2 weeks.

Institutional Billing Info

Read more

 

Insurance Billing

Patient’s out-of-pocket cost may vary depending on the patient’s health insurance plan. RPRD will contact the patient’s insurance provider to understand the potential total out-of-pocket cost (estimated only). We promise to process the test only if the patient is comfortable with the cost. RPRD also offers Financial Assistance Program to eligible patients to help reduce the out-of-pocket costs.

RPRD’s Financial Assistance Program 

If you have any questions about your patient’s test results or need any help to understand the report, our board-certified medical geneticist and experienced PGx scientists are available to guide you through the test results and answer any questions.

We do not offer consultation to the patients directly.

 

Test menu

At RPRD, we offer a wide range of PGx testing service.

Lab accreditation

All samples are processed in our CLIA-certified diagnostic laboratory with robust quality assurance programs that surpass required diagnostic testing standards.